MORGAN STANLEY PLC/CALL/BIOGEN IDEC/260/0.01/20.06.25 Stock

Warrant

DE000MG6CD53

Real-time Bid/Ask 04:03:01 2024-07-12 am EDT
0.26 EUR / 0.27 EUR +10.42% Intraday chart for MORGAN STANLEY PLC/CALL/BIOGEN IDEC/260/0.01/20.06.25
Current month+6.19%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-12 0.25 +4.17%
24-07-11 0.24 +9.59%
24-07-10 0.219 +6.83%
24-07-09 0.205 -1.44%
24-07-08 0.208 +7.22%

Delayed Quote Börse Stuttgart

Last update July 12, 2024 at 03:37 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BIOGEN INC.
Issuer Morgan Stanley
WKN MG6CD5
ISINDE000MG6CD53
Date issued 2024-06-20
Strike 260 $
Maturity 2025-06-20 (344 Days)
Parity 100 : 1
Emission price 0.24
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.27
Lowest since issue 0.193
Delta0.52x
Omega 4.287
Premium21.98x
Gearing8.21x
Moneyness 0.9108
Difference Strike 23.2 $
Difference Strike %+8.92%
Spread 0.01
Spread %3.70%
Theoretical value 0.2650
Implied Volatility 36.19 %
Total Loss Probability 61.60 %
Intrinsic value 0.000000
Present value 0.2650
Break even 288.85 €
Theta-0x
Vega0.01x
Rho0.01x

Company Profile

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.
Sector
-
More about the company

Ratings for Biogen Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Biogen Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
236.8 USD
Average target price
282 USD
Spread / Average Target
+19.10%
Consensus